China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
 & Lead Plaintiff Deadline - March 27, 2017 - EconoTimes)
NEW YORK, March 23, 2017 -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against ReWalk Robotics Ltd. (“ReWalk” or the “Company”) (NASDAQ:RWLK) and certain of its officers, on behalf of a class who purchased ReWalk securities pursuant to the Company’s initial public offering (“IPO”) on or around September 12, 2014. Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/rwlk.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
ReWalk is a medical commercial bionic walking assistance system. The company designs, develops, and commercializes exoskeletons for wheelchair-bound individuals.
The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements in its Registration Statement and Prospectus issued in regards with the Initial Public Offering did not disclose material information, including that ReWalk could not comply with “special controls” requirements or to offer the U.S. Food and Drug Administration with a post market surveillance study. Once this information was made public, ReWalk stock price dropped, causing investors harm.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/rwlk or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in ReWalk you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
